Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Free Cash Flow: 2022-2025

Historic Free Cash Flow for Day One Biopharmaceuticals (DAWN) over the last 4 years, with Sep 2025 value amounting to -$5.8 million.

  • Day One Biopharmaceuticals' Free Cash Flow fell 105.53% to -$5.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$139.2 million, marking a year-over-year decrease of 54.25%. This contributed to the annual value of -$98.1 million for FY2024, which is 33.29% up from last year.
  • Latest data reveals that Day One Biopharmaceuticals reported Free Cash Flow of -$5.8 million as of Q3 2025, which was up 74.90% from -$23.1 million recorded in Q2 2025.
  • In the past 5 years, Day One Biopharmaceuticals' Free Cash Flow ranged from a high of $105.0 million in Q3 2024 and a low of -$104.1 million during Q2 2024.
  • Over the past 3 years, Day One Biopharmaceuticals' median Free Cash Flow value was -$41.4 million (recorded in 2023), while the average stood at -$30.5 million.
  • Over the last 5 years, Day One Biopharmaceuticals' Free Cash Flow had its largest YoY gain of 382.99% in 2024, and its largest YoY loss of 144.54% in 2024.
  • Day One Biopharmaceuticals' Free Cash Flow (Quarterly) stood at -$35.3 million in 2022, then dropped by 17.19% to -$41.4 million in 2023, then decreased by 19.04% to -$49.3 million in 2024, then tumbled by 105.53% to -$5.8 million in 2025.
  • Its Free Cash Flow was -$5.8 million in Q3 2025, compared to -$23.1 million in Q2 2025 and -$61.0 million in Q1 2025.